This course is designed for pharmacists and/or other healthcare professionals involved in the medication management of individuals living with psychiatric, neurologic and/or substance use disorders.
Session Summary
Currently established medication options available for the treatment of psychiatric and neurologic disorders may still result in poor patient response. Outside of the development of new medications to target various psychiatric disease states, the repurposing/off-label use of medications indicated for use in other disorders may provide alternative treatment options. Off-label uses are very common in neurologic and psychiatric conditions, and while they can provide needed treatments for obscure or treatment-refractory conditions, evidence supporting their use is typically limited. Safety, adverse effects, cost, and effectiveness need to be considered and a psychiatric pharmacist is well-suited to provide recommendations by staying up to do with current research. After this presentation, the audience should be familiar with some of the latest research of neurologic and psychiatric drugs which are being investigated for new disease states and finding new therapeutic uses.
Course Requirements
You will proceed through the following steps to satisfactorily complete this course:
Sign in (or create a FREE account).
Register for this course.
Review the full content of the activity and reflect upon its teachings.
Complete the post-test at the end of the activity no later than the closing activity date.
Complete the evaluation at the end of the activity.
If necessary, complete the post-test retest no later than the closing activity date.
Receive a passing grade (70%).
Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at https://aapp.org/mycpnp/transcript/acpe.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
A modern web browser with JavaScript and cookies enabled: Chrome is strongly recommended,
or the latest version of Firefox or Safari.
A PDF reader: Chrome built-in, Firefox built-in, Acrobat
or FoxIt
An adequate device and Internet connection:
Processor: Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent);
Memory: 4 GB;
Storage: 5 GB available;
Internet speed: 4.0 Mbps (up/down)
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Alan Breier, MD
Senior Professor of Psychiatry Vice-Chair for Clinical Research Chief, IU Psychotic Disorders Program Director
Indiana University School of Medicine, Prevention and Recovery Center Indiana University School of Medicine
Indianapolis, IN
Alan Breier, MD attended college at the University of Toledo (B.A. psychology, summa cum laude), medical school at the University of Cincinnati School of Medicine, and trained in psychiatry at Yale University School of Medicine. Following Yale, he completed a three year research fellowship in the NIMH Intramural Research Program (IRP). Following research training, Dr. Breier was appointed Associate Research Professor of Psychiatry at the University of Maryland School of Medicine and Maryland Psychiatric Research Center where he directed a research program for patients with schizophrenia. Dr. Breier and his Maryland research team employed brain imaging techniques to better understand the pathophysiology of schizophrenia and examined potential mechanisms relevant to novel therapeutics for this disorder. He was Principle Investigator of a federal grant (R01) that focused on the efficacy and safety of the second generation antipsychotic drug clozapine in partial responding schizophrenic outpatients and utilized MRI to examine brain correlates of treatment effects. In addition, he was a steering committee member for a NIMH funded center grant that focused on schizophrenia. Dr. Breier then returned to the NIMH IRP in a tenured position to resume study of severe psychiatric disorders. He developed a novel PET scan paradigm to assess neurotransmitter function in schizophrenia, examined genetic hypotheses of antipsychotic drug response and explored mechanisms of action of putative novel therapeutics. Dr. Breier was then recruited to Eli Lilly and Company as a Lilly Research Fellow. He was promoted to Vice President and subsequently promoted to be Lilly’s Chief Medical Officer. As Lilly’s Chief Medical Officer, Dr. Breier had responsibility for all of Lilly’s physicians, global clinical trial scientific staff (statisticians, data managers, clinical research associates, etc), translational medicine including the management of two phase I clinics (Indianapolis and Singapore), pharmacogenomics, clinical biomarker R&D, corporate and regional medical affairs, and global clinical operations which was accountable for clinical trial execution across all phases of clinical development (Phase I-IV) and all therapeutic areas. He chaired the Product Development Committee which provided governance for all phase III programs. As CMO, he was responsible for Lilly’s medical policies and led efforts to enhance trust and transparency of industry medical research. The Principles of Medical Research, which is a set of ethical principles for the conduct, funding and data disclosure of all medical research at Lilly, were introduced and embedded in Lilly’s policies and operating standards. Dr. Breier’s current position is Indiana University Mental Health Research and Education Senior Professor of Psychiatry and Vice-Chair for Clinical Research in the Department of Psychiatry, Indiana University School of Medicine where he is also Chief of the IU Psychotic Disorders Program. He established the Prevention and Recovery Center for Early Psychosis (PARC) in 2009 which is a treatment and research center for young individuals in the earliest stages of psychotic illness. PARC has provided clinical services to over 600 young people who showed the earliest signs of schizophrenia with the goal preventing the downward slide into lifelong chronic schizophrenia. PARC has two federal grants to offer Clinical Specialty Care, a state of the art treatment model for early stage psychosis, for both “in clinic” and tele-health populations. His team is currently investigating several novel treatments for schizophrenia including neuroprotective agents in first-episode psychosis. Dr. Breier has published over 250 scientific articles and is recipient of numerous awards including the American Psychiatric Association’s Nancy C. A. Roeske Certificate of Excellence for Medical Student Education.
Faculty Disclosures
Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: N-acetyl cysteine, valacyclovir, estrogen receptor beta agonist (LY500307)
All relevant relationships have been mitigated.
Learning Objectives
Discuss what is known about the causes of schizophrenia and their implications for novel treatments.
Review new evidence supporting innovative neuroprotective and anti-inflammatory agents for schizophrenia.
Recognize unique treatment considerations in first-episode schizophrenia.
Describe the role of the psychiatric pharmacist in clinical and research aspects of first episode schizophrenia.
Continuing Education Credit and Disclosures
Activity Dates:06/01/2018 - 04/23/2021 ACPE Contact Hours: 1 ACPE Number: 0284-0000-18-031-H01-P (Knowledge) Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hour of knowledge-based continuing education credit from CPNP approved programming.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Elayne D. Ansara, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist
Richard L. Roudebush VAMC
Indianapolis, IN
No Relevant Financial Relationships to Disclose
Jennifer Bean, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist
VA-Tennessee Valley Healthcare System
Murfreesboro, TN
Employment: VA-Tennessee Valley Healthcare System, Clinical Pharmacy Specialist, University of Tennessee, College of Pharmacy Assistant Professor without Tenure
Educational Grants, Research Grants or Contracts: American Society of Health System, Federal Grant Co-Investigator
Jolene R. Bostwick, PharmD, BCPS, BCPP
Associate Chair & Clinical Associate Professor, Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Ann Arbor, MI
No Relevant Financial Relationships to Disclose
Sheila R. Botts, PharmD, BCPP, FCCP
Chief of Clinical Pharmacy Research and Academic Affairs
Kaiser Permanente-Colorado
Aurora, CO
Educational Grants, Research Grants or Contracts: Kaiser Permanente Center for Safety and Effectiveness
Non-Financial Interests: Board of Pharmacetical Specialties Psychiatric Pharmacy Specialty Council
Bridget Bradley, PharmD, BCPP
Associate Professor
Pacific University School of Pharmacy
Hillsboro, OR
Educational Grants, Research Grants or Contracts: NACDS Community Pharmacy Residency Grant
Austin R. Campbell, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
University of Missouri Health Care
Columbia, MO
No Relevant Financial Relationships to Disclose
Andria F. Church, PharmD, BCPS
Assistant Professor
Larkin University College of Pharmacy
Miami, FL
No Relevant Financial Relationships to Disclose
Kelly N. Gable, PharmD, BCPP
Associate Professor
SIUE School of Pharmacy
Edwardsville, IL
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Places for People, Psychiatric Clinical Pharmacist, Family Care Health Centers, Psychiatric Clinical Pharmacist
Educational Grants, Research Grants or Contracts: SAMHSA GLS campus suicide prevention grant
Kristen N. Gardner, PharmD
Clinical Pharmacy Specialist - Behavioral Health
Kaiser Permanente Colorado
Denver, CO
Employment: Kaiser Permanente Colorado
Cindy A. Gutierrez, PharmD, BCPP, MS
Program Committee Chair
Associate Chief, Clinical Pharmacy Programs
South Texas Veterans Health Care System
San Antonio, TX
No Relevant Financial Relationships to Disclose
Robert J. Haight, PharmD, BCPP
Clinical Pharmacy Specialist-Psychiatry
University of MN Medical Center
Minneapolis, MN
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: HealthPartners - Behavioral Health Advisory Group (Unpaid)
Michael Kotlyar, PharmD, MS
Associate Professor
University of Minnesota
Minneapolis, MN
No Relevant Financial Relationships to Disclose
Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey
Long Branch, NJ
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Pharmacy Times, Jannsen Pharmacueticals - Advisory board, Otsuka Pharmaceuticals - Speakers Bureau
Leigh Anne Nelson, PharmD, BCPP
Associate Professor
University of Missouri-Kansas City
Kansas City, MO
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Alexza Pharmaceuticals
Educational Grants, Research Grants or Contracts: Otsuka, Eli Lilly
Rosana C. Oliveira, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist - Psychiatry
South Texas Veterans Health Care System
San Antonio, TX
No Relevant Financial Relationships to Disclose
Gerald P. Overman, PharmD, BCPP
Program Administrative Chair
Clinical Pharmacy Specialist, NIMH
National Institutes of Health
Bethesda, MD
No Relevant Financial Relationships to Disclose
Emma C. Palmer, PharmD, BCPS, BCPP
Assistant Professor of Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Louisville, KY
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Naloxone Access in Kentucky by Pharmacists- Certification contact hours provider
Educational Grants, Research Grants or Contracts: Sullivan University College of Pharmacy internal research grant
Non-Financial Interests: Kentucky Society of Health-Systems Pharmacists (KSHP) Chair of House of Delegates
Lindsey Peters, PharmD, BCPS
Assistant Professor of Pharmacy Practice
Ohio Northern University
Ada, OH
No Relevant Financial Relationships to Disclose
Melody Ryan, PharmD, BCPS, BCGP, FCCP
Professor
University of Kentucky
Lexington, KY
No Relevant Financial Relationships to Disclose
Kristyn Straw, PharmD, BCPP
Mental Health Pharmacist
Southern Arizona VA Health Care System
Tucson, AZ
No Relevant Financial Relationships to Disclose
Daina Wells, PharmD, BCPP, BCPS
National Program Manager, Academic Detailing
VACO PBM
San Francisco, CA
No Relevant Financial Relationships to Disclose
Gabriela D. Williams, PharmD, BCPS, BCPP
Clinical Pharmacy Specialist, Psychiatry
Eskenazi Health
Indianapolis, IN
No Relevant Financial Relationships to Disclose
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: N-acetyl cysteine, valacyclovir, estrogen receptor beta agonist (LY500307)
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.
System Update:
We are undergoing major upgrades right now, and we appreciate your patience.
If you need help, please use the support chat or email info@aapp.org.
Learn more.